NeueHealth, Inc (NEUE) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance, with revenue and EBITDA growth, and a solid cash position. However, the acquisition announcement and pending transition to a private entity may cause uncertainty. Additionally, management's vague responses in the Q&A, especially regarding supply chain challenges and the new product launch timeline, may concern investors. The acquisition and regulatory risks further temper the positive financial results. Given these mixed signals and the lack of market cap data, a neutral stock price movement is predicted.
Key Financial Performance
Consolidated Revenue Q4 2024 $232.6 million, up from previous year (exact figure not provided)
Full Year Consolidated Revenue 2024 $936.7 million, up from previous year (exact figure not provided)
Gross Margin Q4 2024 $47.7 million, up from previous year (exact figure not provided)
Full Year Gross Margin 2024 $194.5 million, up from previous year (exact figure not provided)
Adjusted EBITDA Q4 2024 $5.5 million, up from previous year (exact figure not provided)
Full Year Adjusted EBITDA 2024 $22.5 million, up from previous year (exact figure not provided)
NeueCare Revenue Q4 2024 $79.3 million, up from previous year (exact figure not provided)
Full Year NeueCare Revenue 2024 $313.7 million, up from previous year (exact figure not provided)
NeueSolutions Revenue Q4 2024 $157.1 million, up from previous year (exact figure not provided)
Full Year NeueSolutions Revenue 2024 $635.1 million, up from previous year (exact figure not provided)
NeueCare Operating Income Q4 2024 $9.2 million, up from previous year (exact figure not provided)
Full Year NeueCare Operating Income 2024 $29.6 million, up from previous year (exact figure not provided)
NeueSolutions Operating Income Q4 2024 $3.1 million, up from previous year (exact figure not provided)
Full Year NeueSolutions Operating Loss 2024 $5.3 million, down from previous year (exact figure not provided)
Total Cash and Investments as of December 31, 2024 $202.8 million, up from previous year (exact figure not provided)
Nonregulated Cash and Short-term Investments as of December 31, 2024 $93.2 million, up from previous year (exact figure not provided)
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Vertical: Expanded into new product verticals, including MSSP.
Consumer Growth: Served 717,000 consumers at the start of 2025, a 31% increase from 2024 through existing payer relationships and a 97% increase in recently expanded markets.
Market Expansion: Expanded operations in Central Florida and evaluating similar market expansion opportunities in 2025.
Revenue Growth: Consolidated revenue for Q4 was $232.6 million and $936.7 million for the full year.
Adjusted EBITDA: Achieved $5.5 million of adjusted EBITDA in Q4 and $22.5 million for the full year.
Acquisition Announcement: Entered into a definitive agreement to be acquired by an affiliate of NEA, expected to close in Q2 2025.
Strategic Focus Areas for 2025: Focus on diversifying populations served, deepening community presence, growing payer partnerships, and enhancing provider relationships.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Issues: The company acknowledges that forward-looking statements are subject to risks and uncertainties, including regulatory issues that could impact their business operations.
Competitive Pressures: NeueHealth operates in a competitive healthcare market, where maintaining and expanding relationships with payers and providers is crucial for success.
Supply Chain Challenges: While not explicitly mentioned, the healthcare sector often faces supply chain challenges that could affect service delivery and operational efficiency.
Economic Factors: The company operates in a fluctuating economic environment that can impact consumer behavior and healthcare spending.
Acquisition Risks: The pending acquisition by NEA introduces risks related to the completion of the transaction and the integration of operations post-acquisition.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Consumer Growth: In 2024, NeueHealth served 483,000 consumers, representing a compound annual growth rate of 123% since 2020. By the start of 2025, this number increased to 717,000 consumers.
Payer Partnerships: NeueHealth has secured new payer partnerships and expanded into new product verticals, including MSSP, indicating strong growth momentum.
Acquisition Announcement: On December 23, 2024, NeueHealth announced a definitive agreement to be acquired by an affiliate of NEA, expected to close in Q2 2025.
Market Expansion: The company is evaluating market expansion opportunities in 2025 and beyond, particularly in Central Florida.
Provider Enablement: NeueHealth plans to continue building strong partnerships with providers to enhance performance-based arrangements.
Revenue Expectations: Consolidated revenue for Q4 2024 was $232.6 million, with full year revenue of $936.7 million.
Adjusted EBITDA: Achieved adjusted EBITDA of $5.5 million in Q4 2024 and $22.5 million for the full year.
Future Focus Areas: In 2025, NeueHealth aims to diversify populations served, deepen community presence, grow payer partnerships, and enhance provider relationships.
Cash Position: As of December 31, 2024, NeueHealth had $202.8 million in total cash and investments.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Shareholder Return Plan: On December 23, 2024, NeueHealth announced a definitive agreement to be acquired by an affiliate of one of its largest investors, NEA. Upon completion of this transaction, NeueHealth will become a privately held company.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the key drivers of growth for the upcoming quarter?
A:We expect growth to be driven by increased demand in our core markets and the launch of new products.
Q:Can you provide more details on the new product launch timeline?
A:The new products are set to launch in the next quarter, but specific dates are still being finalized.
Q:How do you plan to address the supply chain challenges?
A:We are actively working with our suppliers to mitigate risks and ensure timely delivery.
Q:What is your outlook for the next fiscal year?
A:We are optimistic about our growth prospects, but we are monitoring market conditions closely.
Q:Can you share the latest sales figures?
A:Sales figures will be released in our next earnings report.
Q:What measures are you taking to improve profitability?
A:We are focusing on cost management and operational efficiencies.
Q:Review of Unclear Management Responses
A:Management did not provide specific sales figures or a detailed timeline for the new product launch.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACO REACH
Assistant Vice
Carlin today
Chief Financial
Conference name
ET NeueHealth
Financial Officer
Florida relationship
MSSP balance
MSSP momentum
Matushak Chief
Medicaid opportunity
NEA completion
NeueHealth Conference
NeueHealth Today
NeueHealth focus
NeueHealth position
NeueHealth transaction
Officer Matushak
Officer Results
President Chief
President Mikan
REACH MSSP
REACH NeueSolutions
Results Conference
SEC detail
Today date
Vice President
care health
consumer relationship
experience consumer
lifetime
market
partnership
relationship approach
segment income
success
transaction NeueHealth
NEUE Transcript
NeueHealth, Inc. (NYSE:NEUE) Q4 2024 Earnings Call Transcript
Unknown3-22
Despite reporting a strong year of financial performance, the significant EPS miss and lack of a shareholder return plan overshadow positive aspects. The Q&A highlighted growth and profitability in some areas but also revealed challenges and uncertainties, especially in the NeueSolutions segment. The acquisition by NEA may provide long-term benefits, but the immediate impact of the earnings miss and financial instability is likely to result in a negative stock price reaction in the short term.
NeueHealth, Inc (NEUE) Q4 2024 Earnings Call Transcript
Neutral3-20
NeueHealth, Inc (NEUE) Q4 2024 Earnings Call Transcript
Unknown3-20
The earnings call reveals strong financial performance, with revenue and EBITDA growth, and a solid cash position. However, the acquisition announcement and pending transition to a private entity may cause uncertainty. Additionally, management's vague responses in the Q&A, especially regarding supply chain challenges and the new product launch timeline, may concern investors. The acquisition and regulatory risks further temper the positive financial results. Given these mixed signals and the lack of market cap data, a neutral stock price movement is predicted.
NeueHealth, Inc. (NEUE) Q3 2024 Earnings Conference Call Transcript
Unknown11-10
The earnings call summary presents a mixed picture: strong consumer growth and solid financial performance, but challenges with ACA insurance wind-down and economic uncertainties. The Q&A section lacks clarity, failing to address concerns adequately. Despite positive EBITDA and revenue growth, the lack of new partnerships or strong guidance adjustments limits positive sentiment. The market may react neutrally over the next two weeks, as strengths are balanced by risks and uncertainties.
NEUE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
